128 related articles for article (PubMed ID: 9241095)
1. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics.
Dingemanse J; Kleinbloesem CH; Zürcher G; Wood ND; Crevoisier C
Br J Clin Pharmacol; 1997 Jul; 44(1):41-8. PubMed ID: 9241095
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
3. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
Crevoisier C; Monreal A; Metzger B; Nilsen T
Eur Neurol; 2003; 49(1):39-44. PubMed ID: 12464717
[TBL] [Abstract][Full Text] [Related]
4. Effects of food on the pharmacokinetics of levodopa in a dual-release formulation.
Crevoisier C; Zerr P; Calvi-Gries F; Nilsen T
Eur J Pharm Biopharm; 2003 Jan; 55(1):71-6. PubMed ID: 12551706
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.
Silveira P; Vaz-da-Silva M; Almeida L; Maia J; Falcão A; Loureiro A; Torrão L; Machado R; Wright L; Soares-da-Silva P
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):603-9. PubMed ID: 14517707
[TBL] [Abstract][Full Text] [Related]
7. Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.
Keller GA; Czerniuk P; Bertuola R; Spatz JG; Assefi AR; Di Girolamo G
Clin Ther; 2011 Apr; 33(4):500-10. PubMed ID: 21635995
[TBL] [Abstract][Full Text] [Related]
8. The effect of tolcapone on the pharmacokinetics of benserazide.
Jorga KM; Larsen JP; Beiske A; Schleimer M; Fotteler B; Schmitt M; Moe B
Eur J Neurol; 1999 Mar; 6(2):211-9. PubMed ID: 10053234
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
Vaz-da-Silva M; Loureiro AI; Nunes T; Lopes C; Rocha J; Machado R; Costa R; Torrão L; Falcão A; Wright L; Almeida L; Soares-da-Silva P
Drugs R D; 2008; 9(6):435-46. PubMed ID: 18989992
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
11. Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.
Rocha JF; Sicard É; Fauchoux N; Falcão A; Santos A; Loureiro AI; Pinto R; Bonifácio MJ; Nunes T; Almeida L; Soares-da-Silva P
Br J Clin Pharmacol; 2017 Mar; 83(3):540-553. PubMed ID: 27763682
[TBL] [Abstract][Full Text] [Related]
12. Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
Boomsma F; Meerwaldt JD; Man in't Veld AJ; Hovestadt A; Schalekamp MA
J Neurol; 1989 May; 236(4):223-30. PubMed ID: 2760634
[TBL] [Abstract][Full Text] [Related]
13. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
[TBL] [Abstract][Full Text] [Related]
14. A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats.
Grange S; Holford NH; Guentert TW
Pharm Res; 2001 Aug; 18(8):1174-84. PubMed ID: 11587490
[TBL] [Abstract][Full Text] [Related]
15. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
Jorga K; Fotteler B; Schmitt M; Nielsen T; Zürcher G; Aitken J
Eur Neurol; 1997; 38(1):59-67. PubMed ID: 9252801
[TBL] [Abstract][Full Text] [Related]
16. Effect of Opicapone Tablets on Levodopa and 3-O-Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study.
Nomoto M; Takeda A; Iwai K; Nishimura A; Hattori N
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):180-189. PubMed ID: 32416054
[TBL] [Abstract][Full Text] [Related]
17. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
Jorga KM; Sedek G; Fotteler B; Zürcher G; Nielsen T; Aitken JW
Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
[TBL] [Abstract][Full Text] [Related]
18. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
Bonifácio MJ; Sutcliffe JS; Torrão L; Wright LC; Soares-da-Silva P
Neuropharmacology; 2014 Feb; 77():334-41. PubMed ID: 24148813
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group.
Ghika J; Gachoud JP; Gasser U
Clin Neuropharmacol; 1997 Apr; 20(2):130-9. PubMed ID: 9099465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
